According to scientists involved in the project, the Covid-19 vaccine developed by researchers at UFMG (Federal University of Minas Gerais) and Fiocruz (Oswaldo Cruz Foundation) could be tested on humans as early as 2023.
The immune SpiN-TEC has performed well in laboratory and animal studies.
However, the voluntary trial is dependent on meeting Anvisa (National Health Authority) requirements.
The development of the vaccine began in March 2020 by UFMG’s CT Vaccines in partnership with Fiocruz Minas and with the support of the Ministry of Science, Technology and Innovation.
In late July 2021, researchers began applying for authorisation. . .
To read full NEWS and much more, Subscribe to our Premium Membership Plan. Already subscribed? Login Here
